12:00 AM
Aug 11, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AHRO-001: Phase Ib started

AtheroNova said partner CardioNova, a subsidiary of Maxwell Biotech, expanded a double-blind, placebo-controlled, Russian Phase I trial evaluating AHRO-001 to include a Phase Ib portion that will enroll about 48 patients with hypercholesterolemia. The Phase Ib portion will evaluate graduated doses of oral...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >